Eli Lilly has smashed through the $1 trillion valuation barrier, making history as the first healthcare company to do so. This monumental milestone is largely fueled by the soaring demand for their weight-loss drugs, particularly Mounjaro and Zepbound. Investors are buzzing with excitement, as this achievement not only reflects the company's innovative edge but also sets a new benchmark in the pharmaceutical industry.

Key Highlights:

• Eli Lilly's valuation reaches $1 trillion, an unprecedented feat in healthcare.
• Driven by the explosive growth of weight-loss medications.
• Experts predict continued success as demand for effective treatments rises.

Here's the full scoop.